Cost-effectiveness of aficamten for obstructive hypertrophic cardiomyopathy: a model-based analysis from the perspective of the Chinese healthcare system. (PubMed, Front Pharmacol) - Oct 27, 2026 - "With a permanent discontinuation probability of 0.131% per 4-week cycle, the ICER was US$23,888.94/QALY. From the Chinese healthcare system perspective, aficamten plus SoC was cost-effective versus SoC alone for symptomatic oHCM under the base-case assumptions."
HEOR • Journal • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy
|
|
Caicong You; Chaolan Jiang; Feng Zhai; Hongyang Li; Jianpeng Mao; Jingjing Chen
|